Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: skinowski who wrote (708043)	3/23/2020 10:20:03 AM
From: carranza2	1 Recommendation Recommended By locogringo Read Replies (2) \| Respond to of 793845

Remember our discussion about ACE-2? Quoting from a 2005 peer reviewed article: virologyj.biomedcentral.com In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. Note/edit: Glycosylation refers to the attachment process, so in layman’s terms, quinine-derived stuff prevents attachment. I wish these guys would write in a way an interested amateur could comprehend. Message 32612971 Obviously, SARS to which the article refers is not cv-19. But it is a corona virus. Quinine and it’s artificial analogues should have been a serious focus of research from the git-go. If I could find the article, virologists could too.